SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas
Latest Information Update: 17 Dec 2021
Price :
$35 *
At a glance
- Drugs Teprotumumab (Primary)
- Indications Alveolar soft part sarcoma; Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Liposarcoma; Myxoid liposarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 16 Dec 2021 This trial has been completed in France (End Date: 19 Feb 2014), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 19 Feb 2014), according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in Spain (End Date: 19 Feb 2014), according to European Clinical Trials Database record.